Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: MDV3100

First Posted Date: 2012-03-29

Last Posted Date: 2019-04-22

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT01565928

Locations: 🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers

Phase 1

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: fesoterodine fumarate

First Posted Date: 2012-03-29

Last Posted Date: 2016-08-19

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT01566760

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Post Marketing Surveillance Study on Linezolid

Completed

Conditions: Gram-Positive Bacterial Infections

Interventions: Drug: Linezolid

First Posted Date: 2012-03-28

Last Posted Date: 2012-08-06

Lead Sponsor: Pfizer

Target Recruit Count: 99

Registration Number: NCT01564758

Serotype Distribution of Chest X-ray Confirmed Pneumococcal Community Acquired Pneumonia in the Adult Population in Greece, Over 1 Year.

Completed

Conditions: Pneumococcal Disease

Interventions: Other: Non Intervention

First Posted Date: 2012-03-28

Last Posted Date: 2018-12-03

Lead Sponsor: Pfizer

Target Recruit Count: 293

Registration Number: NCT01564771

Locations: 🇬🇷
General Hospital of Kavala/ A Pneumonological Clinic, Kavala, Greece
🇬🇷
Diagnostic Therapeutic Center of Athens Ygeia, Athens, Greece
🇬🇷
General University Hospital "Attikgeneral University Hospital "Attikon"/ 4Th University Internal Med, Athnens, Greece

and more 18 locations

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: FLAG (fludarabine, cytarabine and G-CSF)
Drug: inotuzumab ozogamicin
Drug: HIDAC (high dose cytarabine)
Drug: cytarabine and mitoxantrone

First Posted Date: 2012-03-28

Last Posted Date: 2019-01-09

Lead Sponsor: Pfizer

Target Recruit Count: 326

Registration Number: NCT01564784

Locations: 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
Investigational Drug Services - UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
UC San Diego Medical Center - La Jolla, La Jolla, California, United States

and more 189 locations

A Study Comparing PF-05089771 TS Tablet to PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And Fed State

Phase 1

Completed

Conditions: Pain

Interventions: Drug: PF-05089771

First Posted Date: 2012-03-27

Last Posted Date: 2012-03-27

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01563497

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Phase 1

Terminated

Conditions: Metastatic Pancreatic Adenocarcinoma
BRAF Mutated Melanoma

Interventions: Drug: MEK162
Drug: AMG 479

First Posted Date: 2012-03-26

Last Posted Date: 2020-12-10

Lead Sponsor: Pfizer

Target Recruit Count: 77

Registration Number: NCT01562899

Locations: 🇺🇸
Massachusetts General Hospital Mass General 2, Boston, Massachusetts, United States
🇺🇸
University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City, Utah, United States
🇬🇧
Pfizer Investigative Site, Sutton, Surrey, United Kingdom

A Study of ARRY-502 in Patients With Persistent Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo; oral
Drug: ARRY-502, CRTh2 antagonist; oral

First Posted Date: 2012-03-23

Last Posted Date: 2023-10-30

Lead Sponsor: Pfizer

Target Recruit Count: 184

Registration Number: NCT01561690

Locations: 🇺🇸
Allergy Medical Clinic - Research Division, Los Angeles, California, United States
🇺🇸
Chesapeake Clinical Research Inc, Baltimore, Maryland, United States
🇺🇸
Asthma Inc., Seattle, Washington, United States

and more 39 locations

Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin

Completed

Conditions: Hospital-Acquired Pneumonia
Methicillin-Resistant Staphylococcus Aureus (MRSA)

Interventions: Drug: Linezolid
Drug: Vancomycin

First Posted Date: 2012-03-23

Last Posted Date: 2014-07-10

Lead Sponsor: Pfizer

Target Recruit Count: 188

Registration Number: NCT01561469

Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain

Phase 2

Completed

Conditions: Pain

Interventions: Drug: Ibuprofen/acetaminophen
Drug: Placebo
Drug: Ibuprofen

First Posted Date: 2012-03-21

Last Posted Date: 2020-05-19

Lead Sponsor: Pfizer

Target Recruit Count: 394

Registration Number: NCT01559259

Locations: 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy